Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.

Post-translational modifications (PTMs) allot versatility to the biological functions of highly conserved proteins. Recently, modifications to non-histone proteins such as methylation, acetylation, phosphorylation, glycosylation, ubiquitination, and many more have been linked to the regulation of pivotal pathways related to cellular response and stability. Due to the roles these dynamic modifications assume, their dysregulation has been associated with cancer and many other important diseases such as inflammatory disorders and neurodegenerative diseases. For this reason, we present a review and perspective on important post-translational modifications on non-histone proteins, with emphasis on their roles in diseases and small molecule inhibitors developed to target PTM writers. Certain PTMs' contribution to epigenetics has been extensively expounded; yet more efforts will be needed to systematically dissect their roles on non-histone proteins, especially for their relationships with nononcological diseases. Finally, current research approaches for PTM study will be discussed and compared, including limitations and possible improvements.

[1]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Cooper,et al.  Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle , 2001, Cellular and Molecular Life Sciences CMLS.

[3]  T. Kundu,et al.  Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[4]  C. Ackerley,et al.  Peptidylarginine deiminase 2 ( PAD 2 ) overexpression in transgenic mice leads to myelin loss in the central nervous system , 2022 .

[5]  B. Cuevas,et al.  Role of mitogen-activated protein kinase kinase kinases in signal integration , 2007, Oncogene.

[6]  Wei-Guo Zhu,et al.  Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. , 2009, Neoplasia.

[7]  D. Aswad,et al.  Autoimmunity to isomerized histone H2B in systemic lupus erythematosus , 2013, Autoimmunity.

[8]  E. Verdin,et al.  HAT trick: p300, small molecule, inhibitor. , 2010, Chemistry & biology.

[9]  P. Crespo,et al.  Lysine methylation in cancer: SMYD3‐MAP3K2 teaches us new lessons in the Ras‐ERK pathway , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[11]  Yusuke Nakamura,et al.  Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy , 2016, Cancer science.

[12]  P. Carter,et al.  Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. , 2009, Blood.

[13]  S. Wheatley,et al.  Mitotic activity of survivin is regulated by acetylation at K129 , 2015, Cell cycle.

[14]  Kotb Abdelmohsen,et al.  Posttranslational control of HuR function , 2017, Wiley interdisciplinary reviews. RNA.

[15]  Gerald W. Hart,et al.  Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins , 2007, Nature.

[16]  Brent R. Martin,et al.  Large-scale profiling of protein palmitoylation in mammalian cells , 2009, Nature Methods.

[17]  N. L. La Thangue,et al.  Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses , 2016, Scientific Reports.

[18]  J. Hodgin,et al.  Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice , 2014, Annals of the rheumatic diseases.

[19]  A. Degterev,et al.  Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors , 2015, Chemistry & biology.

[20]  C. Der,et al.  Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.

[21]  J. Chien,et al.  Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells* , 2016, The Journal of Biological Chemistry.

[22]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[23]  Huapeng Zhang,et al.  MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma , 2016, Oncotarget.

[24]  Rongsheng E. Wang,et al.  Antibody-drug conjugates for non-oncological indications , 2016, Expert opinion on biological therapy.

[25]  Mike Tyers,et al.  An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme , 2011, Cell.

[26]  P. Thompson,et al.  Design, Synthesis, and Biological Evaluation of Tetrazole Analogs of Cl-Amidine as Protein Arginine Deiminase Inhibitors , 2015, Journal of medicinal chemistry.

[27]  Leilei Yan,et al.  Labeling lysine acetyltransferase substrates with engineered enzymes and functionalized cofactor surrogates. , 2013, Journal of the American Chemical Society.

[28]  B. Chait,et al.  Quantitative chemical proteomics approach to identify post-translational modification-mediated protein-protein interactions. , 2012, Journal of the American Chemical Society.

[29]  I. Sanz,et al.  Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. , 2012, Blood.

[30]  K. Ligon,et al.  Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway. , 2016, Cell reports.

[31]  D. Calvisi,et al.  Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease , 2016, Oncotarget.

[32]  E. Conibear,et al.  ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization , 2015, eLife.

[33]  A. Fukamizu,et al.  Regulation of FoxO transcription factors by acetylation and protein-protein interactions. , 2011, Biochimica et biophysica acta.

[34]  F. A. Romero,et al.  Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.

[35]  I. Grundke‐Iqbal,et al.  Glycosylation of microtubule–associated protein tau: An abnormal posttranslational modification in Alzheimer's disease , 1996, Nature Medicine.

[36]  S. Sebti,et al.  Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor(*) , 1995, The Journal of Biological Chemistry.

[37]  M. Tatsuta,et al.  Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor , 2004, Clinical & Experimental Metastasis.

[38]  A. Wiczkowski,et al.  Potential use of histone deacetylase inhibitors in cancer therapy , 2015, Contemporary oncology.

[39]  D. Vigushin,et al.  Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo , 2004, Medical oncology.

[40]  Jian Luo,et al.  Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents , 2013, Molecular Cancer Therapeutics.

[41]  K. Resing,et al.  Mapping protein post-translational modifications with mass spectrometry , 2007, Nature Methods.

[42]  A. N. Meyer,et al.  Novel Lys63-linked ubiquitination of IKKβ induces STAT3 signaling , 2014, Cell cycle.

[43]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Wei Gu,et al.  p53 post-translational modification: deregulated in tumorigenesis. , 2010, Trends in molecular medicine.

[45]  G. Sethi,et al.  Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics. , 2016, Pharmacology & therapeutics.

[46]  András Falus,et al.  Citrullination: a posttranslational modification in health and disease. , 2006, The international journal of biochemistry & cell biology.

[47]  L. Alfredsson,et al.  Immunity to citrullinated proteins in rheumatoid arthritis. , 2008, Annual review of immunology.

[48]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[49]  Mong-Hong Lee,et al.  COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth , 2015, Oncotarget.

[50]  Ricardo Macarron,et al.  Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.

[51]  G. Charron,et al.  Proteomic Analysis of Fatty-acylated Proteins in Mammalian Cells with Chemical Reporters Reveals S-Acylation of Histone H3 Variants , 2011, Molecular & Cellular Proteomics.

[52]  Qi Wang,et al.  Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration. , 2016, Journal of Alzheimer's disease : JAD.

[53]  Scott M Wilson,et al.  Ubiquitin Homeostasis Is Critical for Synaptic Development and Function , 2011, The Journal of Neuroscience.

[54]  L. Attardi,et al.  p53 at a glance , 2010, Journal of Cell Science.

[55]  Miao Zhang,et al.  Lipopolysaccharides Promote S-Nitrosylation and Proteasomal Degradation of Liver Kinase B1 (LKB1) in Macrophages in Vivo* , 2015, The Journal of Biological Chemistry.

[56]  Ming-Ming Zhou,et al.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.

[57]  Douglas A. Chapnick,et al.  Identification and Mechanistic Studies of a Novel Ubiquitin E1 Inhibitor , 2012, Journal of biomolecular screening.

[58]  U. Oppermann,et al.  Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein , 2011, The EMBO journal.

[59]  Jinping Li,et al.  Nonhistone protein acetylation as cancer therapy targets , 2010, Expert review of anticancer therapy.

[60]  W. Sippl,et al.  KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases. , 2016, Journal of medicinal chemistry.

[61]  G. Davies,et al.  A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. , 2008, Nature chemical biology.

[62]  Jun Yu,et al.  CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancer. , 2014, Carcinogenesis.

[63]  C. Cohen,et al.  Alteration of Forkhead Box O (Foxo4) Acetylation Mediates Apoptosis of Podocytes in Diabetes Mellitus , 2011, PloS one.

[64]  M. Kitagawa,et al.  E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers. , 2016, Current cancer drug targets.

[65]  W. Robinson,et al.  Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination , 2008, Arthritis research & therapy.

[66]  F. Terro,et al.  Post-translational modifications of tau protein: Implications for Alzheimer's disease , 2011, Neurochemistry International.

[67]  C. Arrowsmith,et al.  An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates. , 2016, Journal of proteome research.

[68]  Z. Abbas,et al.  Management of hepatitis delta: Need for novel therapeutic options. , 2015, World journal of gastroenterology.

[69]  Xin Li,et al.  Chemical proteomics approaches to examine novel histone posttranslational modifications. , 2015, Current opinion in chemical biology.

[70]  M. Giacca,et al.  Acetylation by GCN5 regulates CDC6 phosphorylation in the S phase of the cell cycle , 2009, Nature Structural &Molecular Biology.

[71]  S. Anderton.  Post-translational modifications of self antigens: implications for autoimmunity. , 2004, Current opinion in immunology.

[72]  Yuanzhong Wu,et al.  Acetylation-dependent function of human single-stranded DNA binding protein 1 , 2015, Nucleic acids research.

[73]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[74]  Clara D. Christ,et al.  Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2 , 2016, Journal of medicinal chemistry.

[75]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[76]  A. Butte,et al.  SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer , 2014, Nature.

[77]  M. Peter,et al.  Protein neddylation: beyond cullin–RING ligases , 2014, Nature Reviews Molecular Cell Biology.

[78]  Anirvan Ghosh,et al.  Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.

[79]  Jing Zhao,et al.  LRRK2 dephosphorylation increases its ubiquitination , 2015, The Biochemical journal.

[80]  G. Charron,et al.  Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. , 2010, Nature chemical biology.

[81]  S. Sebti,et al.  Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation* , 1996, The Journal of Biological Chemistry.

[82]  Brent R. Martin,et al.  Acyl protein thioesterase inhibitors as probes of dynamic S-palmitoylation. , 2014, MedChemComm.

[83]  G. Monteiro,et al.  Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins , 2015, PloS one.

[84]  Samantha L. Scudder,et al.  Synaptic structure and function are altered by the neddylation inhibitor MLN4924 , 2015, Molecular and Cellular Neuroscience.

[85]  G. F. Ruda,et al.  N-Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus , 2015, ACS chemical biology.

[86]  M. Mann,et al.  Identifying and quantifying in vivo methylation sites by heavy methyl SILAC , 2004, Nature Methods.

[87]  Mike Tyers,et al.  E2 enzyme inhibition by stabilization of a low affinity interface with ubiquitin , 2013, Nature chemical biology.

[88]  H. Qing,et al.  Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. , 2009, Biochemical and biophysical research communications.

[89]  S. Sebti,et al.  Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. , 1999, Cancer research.

[90]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[91]  W. R. Bishop,et al.  Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[92]  Yong Chen,et al.  Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury. , 2015, Journal of molecular and cellular cardiology.

[93]  K. Ha,et al.  Inhibition of Farnesyltransferase Prevents Collagen-Induced Arthritis by Down-Regulation of Inflammatory Gene Expression through Suppression of p21ras-Dependent NF-κB Activation1 , 2004, The Journal of Immunology.

[94]  Yusuke Nakamura,et al.  Critical roles of non-histone protein lysine methylation in human tumorigenesis , 2015, Nature Reviews Cancer.

[95]  N. L. La Thangue,et al.  Post‐translational control of transcription factors: methylation ranks highly , 2015, The FEBS journal.

[96]  Li-Rong Yu,et al.  Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury , 2015, Redox biology.

[97]  H. Krause,et al.  The zebrafish: a powerful platform for in vivo, HTS drug discovery. , 2011, Assay and drug development technologies.

[98]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[99]  K. Hanaoka,et al.  Gliotoxin suppresses NF-κB activation by selectively inhibiting linear ubiquitin chain assembly complex (LUBAC). , 2015, ACS chemical biology.

[100]  Z. Ronai,et al.  Dysregulation of ubiquitin ligases in cancer. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[101]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[102]  R. Marmorstein,et al.  Structure of the α-tubulin acetyltransferase, αTAT1, and implications for tubulin-specific acetylation , 2012, Proceedings of the National Academy of Sciences.

[103]  J. Holst,et al.  p27(Kip1) signaling: Transcriptional and post-translational regulation. , 2015, The international journal of biochemistry & cell biology.

[104]  J. Hanover,et al.  JCB_201501101 1..12 , 2015 .

[105]  Christoph H. Emmerich,et al.  The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system , 2013, The Biochemical journal.

[106]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[107]  J. Hanover,et al.  Distinctive inhibition of O-GlcNAcase isoforms by an α-GlcNAc thiolsulfonate , 2007 .

[108]  M. Murray,et al.  Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. , 2015, Human molecular genetics.

[109]  Peter G Schultz,et al.  Adding new chemistries to the genetic code. , 2010, Annual review of biochemistry.

[110]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[111]  S. Knapp,et al.  The ins and outs of selective kinase inhibitor development. , 2015, Nature chemical biology.

[112]  M. Hung,et al.  Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.

[113]  Min Gyu Lee,et al.  p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.

[114]  S. Sebti,et al.  GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. , 1997, Cancer research.

[115]  T. Pawson,et al.  Reading protein modifications with interaction domains , 2006, Nature Reviews Molecular Cell Biology.

[116]  J. Ji,et al.  BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers , 2015, Molecular Cancer Therapeutics.

[117]  J. Dunne,et al.  Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure? , 2012, Diabetes.

[118]  J. Dou,et al.  A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways , 2014, Cell Death and Disease.

[119]  Jie Liao,et al.  CAAX-box protein, prenylation process and carcinogenesis. , 2009, American journal of translational research.

[120]  R. Watts,et al.  Developing Therapeutic Antibodies for Neurodegenerative Disease , 2013, Neurotherapeutics.

[121]  Yi Zhang,et al.  Tudor, MBT and chromo domains gauge the degree of lysine methylation , 2006, EMBO reports.

[122]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[123]  D. V. van Aalten,et al.  Evidence for a Functional O-Linked N-Acetylglucosamine (O-GlcNAc) System in the Thermophilic Bacterium Thermobaculum terrenum , 2015, The Journal of Biological Chemistry.

[124]  L. Sollid,et al.  Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. , 2011, Current opinion in immunology.

[125]  J. Schellens,et al.  Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.

[126]  W. D. Cress,et al.  THE RETINOBLASTOMA PROTEIN: A MASTER TUMOR SUPPRESSOR ACTS AS A LINK BETWEEN CELL CYCLE AND CELL ADHESION. , 2014, Cell health and cytoskeleton.

[127]  R. Deng,et al.  Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth , 2015, Nature Communications.

[128]  D. Trisciuoglio,et al.  The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target , 2016, Oncotarget.

[129]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[130]  J. Trojanowski,et al.  The acetylation of tau inhibits its function and promotes pathological tau aggregation. , 2011, Nature communications.